Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 6/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1100753 | 0.84 | CYP2C9 (0.51) | CYP2C9CYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL28209330 | 0.80 | IRAK4 (0.53) | CYP2C9CYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17702669 | 0.80 | LMNA (0.48) | — | |
| SCHEMBL3063016 | 0.80 | CYP2C9 (0.47) | CYP2C9CYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8501874 | 0.80 | NPBWR1 (0.47) | — | |
| SCHEMBL4318643 | 0.78 | HDAC6 (0.46) | — | |
| SCHEMBL14493326 | 0.78 | MAPT (0.51) | — | |
| Hydrochloric Acid SCHEMBL32662723 | 0.77 | ALDH1A1 (0.44) | — | |
| SCHEMBL12684800 | 0.76 | LMNA (0.56) | CYP2C9CYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11371864 | 0.76 | TAS2R14 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153385-B2 | Target protein and target gene in drug designing and screening method | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153385-B2 | Target protein and target gene in drug designing and screening method | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20100136524-A1 | TARGET PROTEIN AND TARGET GENE IN DRUG DESIGNING AND SCREENING METHOD | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100136524-A1 | TARGET PROTEIN AND TARGET GENE IN DRUG DESIGNING AND SCREENING METHOD | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136524-A1 | TARGET PROTEIN AND TARGET GENE IN DRUG DESIGNING AND SCREENING METHOD | CHP1, CMA1, CARHSP1 | CYP2C9 2541/4885CYP2C19 3340/4885CYP1A2 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.